

Paolo Nuciforo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7841410/paolo-nuciforo-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

152
papers

7,628
citations

45
h-index

86
g-index

204
ext. papers

9,723
ext. citations

7.5
avg, IF

5.19
L-index

#	Paper	IF	Citations
152	Analysis of persistence and antibiotic response in colorectal cancer. <i>Science</i> , 2017 , 358, 1443-1448	33.3	578
151	Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. <i>Genes and Development</i> , 2006 , 20, 3426-39	12.6	403
150	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. <i>JAMA Oncology</i> , 2015 , 1, 448-54	13.4	359
149	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017 , 24, 311-335	5.1	299
148	NUMB controls p53 tumour suppressor activity. <i>Nature</i> , 2008 , 451, 76-80	50.4	298
147	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in</i>	5.1	293
146	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. <i>Annals of Oncology</i> , 2014 , 25, 1729-1735	10.3	258
145	Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. <i>Nature</i> , 2007 , 448, 1063-7	50.4	249
144	Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. <i>Annals of Oncology</i> , 2014 , 25, 552-563	10.3	242
143	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. <i>Cancer Research</i> , 2017 , 77, 3540-3550	10.1	213
142	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 545-554	21.7	175
141	PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1334-9	2.2	164
140	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. <i>Annals of Oncology</i> , 2018 , 29, 1203-1210	10.3	160
139	The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer. <i>Nature Cell Biology</i> , 2009 , 11, 133-42	23.4	139
138	Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. <i>Cancer Research</i> , 2008 , 68, 7788-94	10.1	138
137	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. <i>Annals of Oncology</i> , 2015 , 26, 1280-91	10.3	127
136	Tankyrase Inhibition Blocks Wnt/ECatenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 644-56	12.9	114

135	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. <i>Oncotarget</i> , 2015 , 6, 37269-80	3.3	112
134	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. <i>Cancer Research</i> , 2017 , 77, 2213-2221	10.1	109
133	Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2017 , 28, 1294-1301	10.3	107
132	Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. <i>Cancer Cell</i> , 2015 , 28, 170-82	24.3	99
131	Breast cancer metastases are molecularly distinct from their primary tumors. <i>Oncogene</i> , 2008 , 27, 2148-58	9.2	97
130	Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. <i>Journal of Clinical Investigation</i> , 2007 , 117, 3436-44	15.9	94
129	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature</i> , 2017 , 547, 109-113	50.4	92
128	Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC). <i>Annals of Oncology</i> , 2017 , 28, v605	10.3	92
127	8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. <i>Genes Chromosomes and Cancer</i> , 2005 , 42, 320-5	5	89
126	A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	85
125	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 227-234	13.4	79
124	The Fragile X Protein binds mRNA s involved in cancer progression and modulates metastasis formation. <i>EMBO Molecular Medicine</i> , 2014 , 6, 567-568	12	78
123	The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation. <i>EMBO Molecular Medicine</i> , 2013 , 5, 1523-36	12	78
122	An atlas of altered expression of deubiquitinating enzymes in human cancer. <i>PLoS ONE</i> , 2011 , 6, e15891	3.7	78
121	Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor. <i>Oncogene</i> , 2009 , 28, 2959-68	9.2	75
120	Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. <i>JAMA Oncology</i> , 2016 , 2, 1287-1294	13.4	65
119	CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003 , 443, 782-6	5.1	65
118	LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8 T cell tumor-infiltration impairing anti-PD1 therapy. <i>Nature Communications</i> , 2019 , 10, 2416	17.4	64

117	Gene expression analysis of early and advanced gastric cancers. <i>Oncogene</i> , 2007 , 26, 4284-94	9.2	60
116	High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. <i>Clinical Cancer Research</i> , 2015 , 21, 569-76	12.9	58
115	Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. <i>Clinical Cancer Research</i> , 2016 , 22, 560-6	12.9	57
114	A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. <i>Pigment Cell and Melanoma Research</i> , 2011 , 24, 326-33	4.5	56
113	FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. <i>Annals of Oncology</i> , 2019 , 30, 1289-1297	10.3	55
112	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1226-1238	21.7	55
111	High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. <i>Molecular Oncology</i> , 2016 , 10, 138-147	7.9	52
110	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 46-54	9.7	48
109	PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. <i>Clinical Cancer Research</i> , 2015 , 21, 2065-74	12.9	47
108	A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CeTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. <i>Annals of Oncology</i> , 2018 , 29, 170-177	10.3	45
107	Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2017 , 28, 2451-2457	10.3	43
106	Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. <i>Scientific Reports</i> , 2013 , 3, 3544	4.9	42
105	Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. <i>Annals of Oncology</i> , 2017 , 28, 128-135	10.3	41
104	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. <i>Journal of Clinical Investigation</i> , 2018 , 128, 3887-3905	15.9	41
103	p95HER2-T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	40
102	Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. <i>Annals of Oncology</i> , 2008 , 19, 1875-81	10.3	39
101	Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. <i>Cancer Discovery</i> , 2013 , 3, 1238-44	24.4	38
100	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. <i>Oncotarget</i> , 2016 , 7, 56295-56308	3.3	38

99	Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system. <i>Journal of Clinical Pathology</i> , 2013 , 66, 124-35	3.9	37
98	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. <i>Nature Communications</i> , 2020 , 11, 385	17.4	36
97	Lymphomas of the bone: a pathological and clinical study of 54 cases. <i>International Journal of Surgical Pathology</i> , 2002 , 10, 257-66	1.2	36
96	Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. <i>Annals of Oncology</i> , 2015 , 26, 1494-500	10.3	34
95	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. <i>Molecular Oncology</i> , 2014 , 8, 150-8	7.9	34
94	Prep1 (pKnox1)-deficiency leads to spontaneous tumor development in mice and accelerates EmuMyc lymphomagenesis: a tumor suppressor role for Prep1. <i>Molecular Oncology</i> , 2010 , 4, 126-34	7.9	32
93	Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. <i>Annals of Oncology</i> , 2020 , 31, 1366-1375	10.3	31
92	DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 341-5	2.7	31
91	Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	31
90	Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. <i>Journal of Autoimmunity</i> , 2019 , 103, 102285	15.5	30
89	Quantification of HER family receptors in breast cancer. <i>Breast Cancer Research</i> , 2015 , 17, 53	8.3	30
88	Early evolutionary divergence between papillary and anaplastic thyroid cancers. <i>Annals of Oncology</i> , 2018 , 29, 1454-1460	10.3	30
87	Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	30
86	Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. <i>PLoS ONE</i> , 2015 , 10, e0129876	3.7	28
85	Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors. <i>Neuroendocrinology</i> , 2012 , 95, 232-47	5.6	26
84	Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	26
83	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. <i>Oncotarget</i> , 2018 , 9, 20617-20630	3.3	26
82	Pirin inhibits cellular senescence in melanocytic cells. <i>American Journal of Pathology</i> , 2011 , 178, 2397-406	6.8	25

81	A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. <i>Annals of Oncology</i> , 2019 , 30, 927-933	10.3	22
80	Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. <i>Journal of Experimental Medicine</i> , 2018 , 215, 1913-1928	16.6	21
79	First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. <i>European Journal of Cancer</i> , 2017 , 81, 142-150	7.5	21
78	Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights. <i>Molecular Oncology</i> , 2017 , 11, 1263-1272	7.9	20
77	Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity. <i>Journal of Experimental Medicine</i> , 2008 , 205, 657-67	16.6	20
76	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. <i>Clinical Cancer Research</i> , 2020 , 26, 738-745	12.9	19
75	Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. <i>Nature Communications</i> , 2021 , 12, 1503	17.4	18
74	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 5820-5829	12.9	17
73	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , 2021 , 299, 109-119	20.5	14
72	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 5499-5510	12.9	13
71	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	12
70	Activity of HSP90 Inhibitor in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 914-917	9.7	12
69	Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies. <i>Regulatory Peptides</i> , 2013 , 187, 35-41		12
68	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. <i>Oncologist</i> , 2019 , 24, 893-900	5.7	12
67	Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. <i>Scientific Reports</i> , 2019 , 9, 13568	4.9	11
66	Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	11
65	Abstract PD3-03: SOLTI-1303 PATRICIA phase II trial (STAGE 1) -- Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer 2019 ,		10
64	LOXL2-mediated H3K4 oxidation reduces LOXL2 accessibility in triple-negative breast cancer cells. <i>Oncogene</i> , 2020 , 39, 79-121	9.2	10

63	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. <i>Clinical Cancer Research</i> , 2020 , 26, 3720-3731	12.9	10
62	Tumor-Associated Microbiome: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	9
61	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, e181564	13.4	8
60	Malakoplakia of the pancreas with diffuse lymph-node involvement. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003 , 442, 82-5	5.1	8
59	Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1289-1297	6.1	7
58	Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic. <i>Cellular Oncology (Dordrecht)</i> , 2015 , 38, 39-48	7.2	7
57	Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 312-317	6.1	6
56	Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Molecular Oncology</i> , 2021 , 15, 887-900	7.9	6
55	Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. <i>ESMO Open</i> , 2019 , 4, e000444	6	5
54	Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial 2018 ,		5
53	Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. <i>Npj Precision Oncology</i> , 2021 , 5, 23	9.8	5
52	Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	5
51	Abstract P5-20-19: PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial 2018 ,		4
50	First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS2619-TPS2619	2.2	4
49	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 571-571	2.2	4
48	On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 574-574	2.2	4
47	PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. <i>British Journal of Cancer</i> , 2021 , 124, 1581-1591	8.7	4
46	Functional Mapping of AKT Signaling and Biomarkers of Response From the FAIRLANE Trial of Neoadjuvant Ipatasertib Plus Paclitaxel for Triple-Negative Breast Cancer.. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4

45	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.. <i>Cancer Research</i> , 2022 , 82, 1646-1657	10.1	4
44	PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial. <i>European Journal of Cancer</i> , 2018 , 92, S117-S118	7.5	3
43	Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer. <i>European Journal of Radiology</i> , 2020 , 133, 109345	4.7	3
42	PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors. <i>Annals of Oncology</i> , 2019 , 30, v760	10.3	2
41	Abstract P1-09-09: Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer 2017 ,		2
40	Matching degree between PI3K/AKT/mTOR (PAM) pathway mutations (mut) and therapy (ttx) as predictor of clinical benefit (ClinBen) in early trials.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2572-2572	2.2	2
39	Patient-derived AVATAR mouse models to predict prognosis in advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 551-551	2.2	2
38	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1025-1025	2.2	2
37	Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1075-1075	2.2	2
36	First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. <i>Frontiers in Oncology</i> , 2021 , 11, 744112	5.3	2
35	Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 528-528	2.2	2
34	Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer. <i>Breast</i> , 2020 , 53, 102-110	3.6	2
33	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. <i>Npj Breast Cancer</i> , 2021 , 7, 73	7.8	2
32	- and -Mutated Chemotherapy and Anti-EGFR-Refractory Colorectal Cancer: Should Clonality Guide Target Prioritization With Investigational Therapies?. <i>JCO Precision Oncology</i> , 2019 , 3, 1-3	3.6	1
31	Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 649-649	3.2	1
30	Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1050-1050	2.2	1
29	Whole exome sequencing (WES) of non-small cell lung cancer (NSCLC) for tumor mutational burden (TMB) analysis and long-term benefit to immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9071-9071	2.2	1
28	Immune profile and outcomes of patients (pts) with gynecological malignancies (GYN) enrolled in early phases immunotherapy (IO) trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5595-5595	2.2	1

27	Analysis of Programmed Death-Ligand 1 Expression, Stromal Tumor-Infiltrating Lymphocytes, and Mismatch Repair Deficiency in Invasive Micropapillary Carcinoma of the Breast. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019 , 2, 130-136	0.6	1
26	Impact of early trials in molecularly-characterized patients (pts) with head and neck cancer (HNC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6031-6031	2.2	1
25	Impact of genomic heterogeneity on PI3K/AKT/mTOR inhibitors (PAMi) efficacy in gynecologic cancer (GYN) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5569-5569	2.2	1
24	RNAseq analysis of the sorafenib phase III DECISION trial in differentiated thyroid cancer (DTC): Correlation with clinical outcome.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6083-6083	2.2	1
23	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 6156-6163	12.9	1
22	High mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	1
21	The Porto European Cancer Research Summit 2021. <i>Molecular Oncology</i> , 2021 , 15, 2507-2543	7.9	1
20	A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 2250-2261	6.1	1
19	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. <i>Npj Breast Cancer</i> , 2021 , 7, 145	7.8	0
18	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 5607-5618	12.9	0
17	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. <i>Clinical Cancer Research</i> , 2021 , 27, 6307-6313	12.9	0
16	Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2021 , 125, 1561-1569	8.7	0
15	Abstract P2-13-12: High CD36 expression predicts worse event free survival in HER2-positive breast cancer patients treated with neoadjuvant trastuzumab-based therapy: An exploratory analysis of the NeoALTTO study. <i>Cancer Research</i> , 2022 , 82, P2-13-12-P2-13-12	10.1	0
14	Abstract P1-07-02: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC). <i>Cancer Research</i> , 2022 , 82, P1-07-02-P1-07-02	10.1	0
13	Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Balmonella typhimurium immunity. <i>Journal of Cell Biology</i> , 2008 , 180, i17-i17	7.3	
12	Real-world data on overall survival (OS) impact of anti-EGFR sequence in patients (pts) with microsatellite stable (MSS) all-RAS and BRAFV600E wild-type metastatic (met) colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3551-3551	2.2	
11	Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome data Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: prevalence and outcome data.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4071-4071	2.2	
10	Concordance of genomic alterations (GA) in synchronous tumor biopsies (tBx) and circulating tumor (ct) DNA from metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1073-1073	2.2	

- 9 The predictive role of plasma mutant allele fraction to antiangiogenic drugs in patients with mCRC: An expanded analysis of surrogate biomarkers of response to first-line treatment with bevacizumab.. *Journal of Clinical Oncology*, **2020**, 38, 3541-3541 2.2
- 8 Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.. *Journal of Clinical Oncology*, **2020**, 38, 511-511 2.2
- 7 Chromosomal rearrangements in acute myeloid leukemia (AML). *Ecancermedicalscience*, **2010**, 4, 183 2.7
- 6 Inflammatory pseudo bladder tumour: Clinical case. *Urologia*, **1997**, 64, 430-433 1.2
- 5 Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2014**, 32, 3591-3591 2.2
- 4 Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d'Hebron Institute of Oncology phase I program cohort.. *Journal of Clinical Oncology*, **2015**, 33, 587-587 2.2
- 3 Measuring the impact of Next Generation Sequencing (NGS) technique implementation in metastatic colorectal cancer (mCRC) drug development program.. *Journal of Clinical Oncology*, **2015**, 33, 3598-3598 2.2
- 2 Molecular markers to predict response to selective fibroblast growth factor receptor inhibitors (FGFRinh) in patients (pts) with FGFR-amplified (amp) or mutated (mut) tumors.. *Journal of Clinical Oncology*, **2017**, 35, 2581-2581 2.2
- 1 Molecular sequencing and gene fusion detection in non-small cell lung cancer (NSCLC) patients: Impact of co-existing alterations.. *Journal of Clinical Oncology*, **2017**, 35, e23103-e23103 2.2